Tectonic Therapeutic, Inc. announced positive interim data from its Phase 1b trial for TX45 in patients with Group 2 pulmonary hypertension on January 30, 2025, and posted a presentation on its website.
AI Assistant
TECTONIC THERAPEUTIC INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.